Edition:
United States

Biomerica Inc (BMRA.OQ)

BMRA.OQ on NASDAQ Stock Exchange Capital Market

4.60USD
23 Feb 2018
Change (% chg)

$0.08 (+1.77%)
Prev Close
$4.52
Open
$4.50
Day's High
$4.64
Day's Low
$4.50
Volume
7,238
Avg. Vol
13,672
52-wk High
$9.32
52-wk Low
$1.96

Chart for

About

Biomerica, Inc. is a biomedical company, which develops, manufactures and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The Company's medical diagnostic products are sold around the world in over two markets, including clinical laboratories and point of... (more)

Overall

Beta: -0.80
Market Cap(Mil.): $39.63
Shares Outstanding(Mil.): 8.54
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 33.67 16.59
EPS (TTM): -- -- --
ROI: -- 14.21 35.07
ROE: -- 16.88 17.79

BRIEF-Biomerica Q2 Loss Per Share $0.03

* BIOMERICA ANNOUNCES SECOND QUARTER FINANCIAL RESULTS; SALES UP 12.7% FOR THE QUARTER

Jan 16 2018

BUZZ-Biomerica: China's FDA approves colorectal screening test for cancer

** Diagnostic test maker's shares up as much as 64.77 pct to touch record high of $7.25 - biggest intraday pct gain since May 2016

Jan 10 2018

BRIEF-China FDA Approves Biomerica Colorectal Screening Test To Help Identify The Early Warning Signs Of Colorectal Cancer

* CHINA FOOD AND DRUG ADMINISTRATION (CFDA) APPROVES BIOMERICA COLORECTAL SCREENING TEST TO HELP IDENTIFY THE EARLY WARNING SIGNS OF COLORECTAL CANCER Source text for Eikon: Further company coverage:

Jan 10 2018

BRIEF-Biomerica Enters Into At Market Issuance Sales Agreement With B. Riley FBR

* BIOMERICA INC - ‍ON DEC. 1, 2017, CO ENTERED INTO AN AT MARKET ISSUANCE SALES AGREEMENT WITH B. RILEY FBR, INC - SEC FILING​

Dec 04 2017

BRIEF-Biomerica extends license agreement with Celtis Pharm

* Biomerica extends exclusive license agreement with Celtis Pharm (Telcon Pharmaceuticals) to December 2019

Nov 07 2017

BRIEF-Biomerica Inc Q1 ‍net sales $1.4 million

* Net sales of $1.4 million for three months ending August 31, 2017, an increase of 2.4%​

Oct 17 2017

BRIEF-Biomerica commences clinical studies for new Gastroenterology H. Pylori test

* Biomerica commences clinical studies for new Gastroenterology H. Pylori test

Sep 12 2017

Earnings vs. Estimates